Association of clinical and genetic risk factors with management of dyslipidaemia: analysis of repeated cross-sectional studies in the general population of Lausanne, Switzerland

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Objectives To assess the importance of clinical and genetic factors in management of dyslipidaemia in the general population. Design Repeated cross-sectional studies (2003–2006; 2009–2012 and 2014–2017) from a population-based cohort. Setting Single centre in Lausanne, Switzerland. Participants 617 (42.6% women, mean±SD: 61.6±8.5 years), 844 (48.5% women, 64.5±8.8 years) and 798 (50.3% women, 68.1±9.2) participants of the baseline, first and second follow-ups receiving any type of lipid-lowering drug. Participants were excluded if they had missing information regarding lipid levels, covariates or genetic data. Primary and secondary outcome measures Management of dyslipidaemia was assessed according to European or Swiss guidelines. Genetic risk scores (GRSs) for lipid levels were computed based on the existing literature. Results Prevalence of adequately controlled dyslipidaemia was 52%, 45% and 46% at baseline, first and second follow-ups, respectively. On multivariable analysis, when compared with intermediate or low-risk individuals, participants at very high cardiovascular risk had an OR for dyslipidaemia control of 0.11 (95% CI: 0.06 to 0.18), 0.12 (0.08 to 0.19) and 0.38 (0.25 to 0.59) at baseline, first and second follow-ups, respectively. Use of newer generation or higher potency statins was associated with better control: OR of 1.90 (1.18 to 3.05) and 3.62 (1.65 to 7.92) for second and third generations compared with first in the first follow-up, with the corresponding values in the second follow-up being 1.90 (1.08 to 3.36) and 2.18 (1.05 to 4.51). No differences in GRSs were found between controlled and inadequately controlled subjects. Similar findings were obtained using Swiss guidelines. Conclusion Management of dyslipidaemia is suboptimal in Switzerland. The effectiveness of high potency statins is hampered by low posology. The use of GRSs in the management of dyslipidaemia is not recommended.
Funding Information
  • Swiss government (Excellence scholarship to VK)
  • GlaxoSmithKline (N/A)
  • Swiss National Science Foundation (33CS30-139468, 33CS30-148401, 33CS30_177535/1, 33CSCO-122661)
  • Faculty of Biology and Medicine of Lausanne (N/A)

This publication has 32 references indexed in Scilit: